Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 (ASAP2) is a multidomain enzyme that contains an N-terminal coiled-coil region, a pleckstrin homology (PH) domain, an Arf-GAP domain, ankyrin repeats, a proline-rich region, and a C-terminal Src homology 3 (SH3) domain[1][3][8]. It is primarily localized in the Golgi apparatus and plasma membrane, where it plays a key role in activating small GTPases (ARF1, ARF5, ARF6), thereby regulating membrane trafficking, vesicle budding, and constitutive cellular secretion[1][2][6][9]. ASAP2 also modulates phagocytosis and cell migration by interacting with cytoskeletal proteins like paxillin and tyrosine kinases such as PYK2 and SRC[1][3]. Its enzyme activity and protein-protein interactions position it as a potential signaling regulator with relevance to cancer cell biology and possibly other pathological processes[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 (ASAP2).